Skip to the page

Data / Form D filings / ABL BIO USA, Inc.

ABL BIO USA, Inc.: Form D filing

ABL BIO USA, Inc., a biotechnology company in Palo Alto, CA, filed a Form D with the SEC in 2023. The latest, on September 7, 2023, reports $3 million sold of a $3 million offering to 1 investor.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
3223 HANOVER ST, SUITE 110, Palo Alto, CA, 94304
Phone
(734) 707-3715
Industry
Biotechnology
Entity type
Corporation
Incorporated in
California
Year incorporated
2022
Revenue range
$1 - $1,000,000
Exemptions claimed
Rule 504, Rule 506(b)
SEC identifier (CIK)
1991318

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Sep 7, 2023New notice$2,999,900$2,999,9001Jul 25, 2023sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Jae Cheon LeeExecutive Officer, Director

Other biotechnology companies in California that filed recently

Every Form D from the week of Sep 4, 2023 · All recent filings in California · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what ABL BIO USA, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.